EN DE
Watch Molecular Partners AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Molecular Partners AG (MOLN) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Molecular Partners AG stock CHF 2.26, price CHF 2.48, that is 8.9% below the price, quality 36 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0256379097

MP Molecular Partners AG logo Thin data Nov 10, 2026

Molecular Partners AG

MOLN · SW

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Fair value CHF 2.26 · Fairly valued 
Price moving sideways (no uptrend) 
Mixed vs. peers (3/6) 
Quality 36/100 
Weak Growth (revenue 5y −24.6 %/yr in CHF) 
Negative free cash flow 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch Molecular Partners AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 28.00 CHF 2.48 Fair Value CHF 2.26 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range CHF 2.48 – CHF 28.00 · fair‑value band CHF 1.70 – CHF 2.83 · the CHF 2.48 price screens above the CHF 2.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Molecular Partners in your weekly email

Every Wednesday you see whether Molecular Partners is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Show moreShow less

Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.

In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.

It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics.

Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Stock analysis

Molecular Partners AG (MOLN) currently trades at CHF 2.48, while our estimate is CHF 2.26, so the stock looks roughly fairly valued today (gap 9.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: CHF 1.70 (bear) to CHF 2.83 (bull), the price of CHF 2.48 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Molecular Partners AG reported revenue of CHF 0 in FY2025 versus CHF 9.3M in FY2021. Reported net income was −CHF 61.7M in FY2025.

Key figures

Market cap CHF 95.1M Micro · EPS (TTM) CHF −1.39 · Return on equity −69.9% · Return on assets (EBIT) −23.2% (5-year average) · Free cash flow −CHF 50.2M · Net cash CHF 79.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −9%, MOLN screens richer than that median.

Fair Value

Bear CHF 1.70 Fair Value CHF 2.26 Bull CHF 2.83
Price CHF 2.48 · Downside -8.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 31
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−29.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.6%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−179.9% (2019) → −1,231.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MOLN, get fair value alerts →

Compare Molecular Partners AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −8.9% · Above median
Profitability
Return on assets −60.4% · Bottom 25%
Operating margin (12 months) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.42× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $951.19 $1,275 +34% vs MOLN
Vertex Pharmaceuticals Incorporated VRTX $542.62 $602.68 +11% vs MOLN
Genmab A/S GMAB kr 3,530 kr 3,917 +11% vs MOLN
Samsung Biologics Co 207940 1,449,000 KRW 1,573,000 KRW +9% vs MOLN
argenx SE ARGX $981.33 $908.40 −7% vs MOLN
CSL Limited CSL A$202.92 A$183.54 −10% vs MOLN
Moderna, Inc MRNA $231.35 $139.99 −39% vs MOLN
BeOne Medicines AG 6160 HK$255.80 HK$152.80 −40% vs MOLN
Celltrion, Inc 068270 209,500 KRW 74,945 KRW −64% vs MOLN
Royalty Pharma plc RPRX $68.97 $19.01 −72% vs MOLN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Molecular Partners AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Molecular Partners AG Fair Value". https://www.fairvalue-calculator.com/stock/MOLN

Frequently asked questions

Is Molecular Partners AG (MOLN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is CHF 2.26 versus a price of CHF 2.48, about 9% lower (fairly valued).
What is the fair value of MOLN?
Our estimate for Molecular Partners AG is CHF 2.26 (as of Nov 10, 2026), built from audited fundamentals. The current price: CHF 2.48.
What is the quality score of MOLN?
Molecular Partners AG has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Molecular Partners AG (MOLN)?
Our calculated price target is the estimate of CHF 2.26 (as of Nov 10, 2026). Cautious scenario CHF 1.70, optimistic scenario CHF 2.83. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Molecular Partners AG stock forecast for 2026?
Our estimate puts fair value at CHF 2.26, about 9% lower versus a price of CHF 2.48 (fairly valued). Cautious scenario CHF 1.70, optimistic scenario CHF 2.83. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Molecular Partners AG (MOLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Molecular Partners AG it is CHF 2.26 per share (as of Nov 10, 2026), against a price of CHF 2.48.
Is Molecular Partners AG stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MOLN trades above its calculated fair value: price CHF 2.48, fair value CHF 2.26, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MOLN?
No. The price is what the market pays today (CHF 2.48); the fair value is what the company's own numbers justify (CHF 2.26). For Molecular Partners AG the two are CHF 0.2200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Molecular Partners AG worth?
The market values Molecular Partners AG at about CHF 95.1M (market capitalisation, as of Nov 10, 2026). Per share that is CHF 2.48; our models calculate a fair value of CHF 2.26 per share.
What do the bullish and bearish scenarios say about MOLN?
Our models span a range for Molecular Partners AG: cautious scenario CHF 1.70, base CHF 2.26, optimistic CHF 2.83 per share (as of Nov 10, 2026, price CHF 2.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Molecular Partners AG (MOLN)?
Balance-sheet figures for Molecular Partners AG (as of Nov 10, 2026): return on equity −69.9%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is MOLN from its 52-week high?
Molecular Partners AG trades at CHF 2.48, about 37% below its 52-week high of CHF 3.95 and at the low of CHF 2.48 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 2.26 is for.
Which stocks are comparable to Molecular Partners AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Molecular Partners AG stock attractive at the current price?
The data as of Nov 10, 2026: price CHF 2.48, calculated fair value CHF 2.26 (−9%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Molecular Partners AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Molecular Partners AG (MOLN)?
The closing price on Nov 12, 2026 was CHF 2.48. Our estimate is CHF 2.26, about 9% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Molecular Partners AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Molecular Partners AG

How large is the market capitalisation of Molecular Partners AG (MOLN)?
The market capitalisation of Molecular Partners AG is CHF 95.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Molecular Partners AG (MOLN)?
Earnings per share at Molecular Partners AG are CHF −1.39. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Molecular Partners AG (MOLN)?
The return on equity (ROE) of Molecular Partners AG is −69.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Molecular Partners AG (MOLN)?
On an EBIT basis the return on assets of Molecular Partners AG is −23.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Molecular Partners AG (MOLN) generate?
The free cash flow of Molecular Partners AG is −CHF 50.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Molecular Partners AG (MOLN) hold?
Molecular Partners AG holds more cash than debt, CHF 79.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Molecular Partners AG in the live analysis

One click puts Molecular Partners AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.